Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit MO, Vincendeau S, Ploussard G, Sargos P. Beauval JB, et al. Among authors: pignot g. Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30. Crit Rev Oncol Hematol. 2018. PMID: 29458782 Review.
Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival.
Colin P, Ouzzane A, Yates DR, Audenet F, Pignot G, Arvin-Berod A, Merigot de Treigny O, Laurent G, Valeri A, Irani J, Saint F, Gardic S, Gres P, Rozet F, Neuzillet Y, Ruffion A, Rouprêt M. Colin P, et al. Among authors: pignot g. Ann Surg Oncol. 2012 Oct;19(11):3613-20. doi: 10.1245/s10434-012-2453-9. Epub 2012 Jul 28. Ann Surg Oncol. 2012. PMID: 22843187
Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Pignot G, Colin P, Zerbib M, Audenet F, Soulié M, Hurel S, Delage F, Irani J, Descazeaud A, Droupy S, Rozet F, Phé V, Ruffion A, Long JA, Crouzet S, Houlgatte A, Bigot P, Guy L, Faïs PO, Rouprêt M; French Collaborative National Database on UUT-UC. Pignot G, et al. Urol Oncol. 2014 Jan;32(1):23.e1-8. doi: 10.1016/j.urolonc.2012.08.010. Epub 2013 Feb 9. Urol Oncol. 2014. PMID: 23403206
Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study.
Pignot G, Salomon L, Neuzillet Y, Masson-Lecomte A, Lebacle C, Patard JJ, Lunardi P, Rischmann P, Pasticier G, Bernhard JC, Cohen J, Timsit MO, Verkarre V, Peyronnet B, Verhoest G, Le Goux C, Zerbib M, Brecheteau F, Bigot P, Larre S, Murez T, Thuret R, Lacarriere E, Champy C, Roupret M, Comperat E, Berger J, Descazeaud A, Toledano H, Bastide C, Lavilledieu S, Avances C, Delage F, Valeri A, Molimard B, Houlgatte A, Gres P, Donnaint A, Kleinclauss F, Legal S, Doerfler A, Koutlidis N, Cormier L, Hetet JF, Colls P, Arvin-Berod A, Rambeaud JJ, Quintens H, Soulie M, Pfister C; Oncologic Committee of the French Association of Urology. Pignot G, et al. Ann Surg Oncol. 2014 Feb;21(2):684-90. doi: 10.1245/s10434-013-3340-8. Epub 2013 Oct 30. Ann Surg Oncol. 2014. PMID: 24170436
Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes.
Bigot P, Hétet JF, Bernhard JC, Fardoun T, Audenet F, Xylinas E, Ploussard G, Pignot G, Bessede T, Ouzaid I, Robine E, Brureau L, Merigot de Treigny O, Maurin C, Long JA, Rouffilange J, Hoarau N, Lebdai S, Rouprêt M, Bastien L, Neuzillet Y, Mongiat-Artus P, Verhoest G, Zerbib M, Ravery V, Rigaud J, Bellec L, Baumert H, Chautard D, Bensalah K, Escudier B, Paparel P, Grenier N, Rioux-Leclercq N, Azzouzi AR, Soulié M, Patard JJ. Bigot P, et al. Among authors: pignot g. Clin Genitourin Cancer. 2014 Feb;12(1):e19-27. doi: 10.1016/j.clgc.2013.09.004. Epub 2013 Sep 28. Clin Genitourin Cancer. 2014. PMID: 24210610
Systemic treatments for high-risk localized prostate cancer.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D. Pignot G, et al. Nat Rev Urol. 2018 Aug;15(8):498-510. doi: 10.1038/s41585-018-0017-x. Nat Rev Urol. 2018. PMID: 29765147 Review.
Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D. Loriot Y, et al. Among authors: pignot g. Cancer Treat Rev. 2018 Nov;70:223-231. doi: 10.1016/j.ctrv.2018.09.006. Epub 2018 Sep 21. Cancer Treat Rev. 2018. PMID: 30300771 Review.
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, Walz J, Pignot G, Rybikowski S, Dermeche S, Thomassin J, Brunelle S, Lavaud P, Loriot Y; French Genito-Urinary Tumor Group (GETUG). Gravis G, et al. Among authors: pignot g. Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11. Eur J Cancer. 2018. PMID: 30316610 No abstract available.
"Real-world" evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy.
Niziers V, Boissier R, Borchiellini D, Deville JL, Khoury C, Durand M, Toledano H, Albert T, Branger N, Bandelier Q, Ouvrier MJ, Gabriel S, Hoch B, Gross E, Walz J, Brenot-Rossi I, Pignot G. Niziers V, et al. Among authors: pignot g. Urol Oncol. 2020 Jan;38(1):2.e1-2.e9. doi: 10.1016/j.urolonc.2019.07.017. Epub 2019 Aug 22. Urol Oncol. 2020. PMID: 31447087
199 results